RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $55
RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $55
RBC資本維持對Agios Pharmaceuticals的跑贏市場評級，並將價格目標上調至55美元。
RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $53 to $55.
RBC Capital的分析師Gregory Renza維持對Agios Pharmaceuticals (NASDAQ:agios pharmaceuticals)的強勁表現並將價格目標從53美元提高至55美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間